Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. arterial intervention
Show results for
Products
Applications

Companies

News

Refine by
Date

  • Older

Arterial Intervention Articles & Analysis

9 news found

An Easy, Predictable, and Simpler Way to Embolize Tumors

An Easy, Predictable, and Simpler Way to Embolize Tumors

(acquired by Cardinal Health in 2014) was founded to address the problem of arterial puncture site closure after interventional procedures. Next came Ocular Therapeutix Inc., to develop an absorbable punctal plug for the extended delivery of drugs to the surface of the eye. ...

ByInstylla, Inc.


XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

Food and Drug Administration (FDA) for XC001 as adjunctive therapy to coronary artery bypass grafting (CABG) in 2H21. The company also plans other clinical studies in additional cardiovascular indications, including heart failure caused by ischemic heart disease and as adjunctive therapy to percutaneous coronary intervention. ...

ByXyloCor Therapeutics


XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease

XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease

About Chronic Refractory Angina In the United States, coronary artery disease is a leading cause of death and disability. Chronic angina pectoris occurs when the heart muscle does not receive sufficient oxygen resulting in chest pain. This is usually due to atherosclerotic plaques that block the coronary arteries. Refractory angina is a growing problem that ...

ByXyloCor Therapeutics


XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT

XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT

About Chronic Refractory Angina In the United States, coronary artery disease is a leading cause of death and disability. Chronic angina pectoris occurs when the heart muscle does not receive sufficient oxygen resulting in chest pain. This is usually due to atherosclerotic plaques that block the coronary arteries. Refractory angina is a growing problem that ...

ByXyloCor Therapeutics


InspireMD Announces Strong Second Quarter 2021 Financial Results

InspireMD Announces Strong Second Quarter 2021 Financial Results

Our ultimate goal is to change the standard of care in the treatment of carotid artery disease away from surgical endarterectomy to the minimally invasive use of CGuard EPS Carotid Stent System. ...

ByInspireMD Inc.


The long-term solution for stressed New York hearts

The long-term solution for stressed New York hearts

Dr. Beheshtian specializes in interventional cardiology and peripheral artery disease, providing top-quality heart care and promoting self-preventive cardiology. ...

ByCoala Life Inc.


XyloCor Therapeutics Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina

XyloCor Therapeutics Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina

The trial will enroll patients who are not responding to medication and are unsuitable for coronary artery bypass graft or percutaneous coronary intervention. XC001 is an investigational novel gene therapy designed to activate naturally occurring biological pathways to improve blood flow to areas of the heart not receiving adequate blood supply. ...

ByXyloCor Therapeutics


Centerline Biomedical Announces First-in-Human Use of IOPS™ Intra-Operative Positioning System

Centerline Biomedical Announces First-in-Human Use of IOPS™ Intra-Operative Positioning System

Ezequiel Parodi of University of North Carolina’s Division of Vascular Surgery, an expert in endovascular aortic interventions, joined staff at the Clinical Centre of Serbia Vascular Centre in repairing two patients’ aortic aneurysms. ...

ByCenterline Biomedical


Imperial Innovations Set to Increase Investment in Veryan Medical

Imperial Innovations Set to Increase Investment in Veryan Medical

The helical curvature also helps the stented vessel mimic the natural biomechanical performance of the femoropopliteal artery during knee flexion, thereby reducing the risk of stent fracture and vessel kinking, which are common problems with traditional straight stents. ...

ByVeryan Medical Ltd.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT